Forget Eli Lilly, Buy This Magnificent Biotech Stock Instead
Lilly is a good pick...but this one is better. Not exactly David vs. Goliath Sure, Vertex is much smaller than Lilly, with the latter's massive market cap at over 120 billion, making it one of the world's largest drugmakers. One nice plus for Vertex is that it enjoys a monopoly in treating the underlying cause of the rare genetic disease cystic fibrosis (CF). All four approved therapies that fit the bill are marketed by Vertex, including it ...